Can I Import My Korean or Japanese Sunscreen Into the U.S. Now?

Since the FDA added bemotrizinol to the OTC sunscreen monograph, brands across Korea, Japan, and Europe are asking the same question: can I finally sell my sunscreen in the United States? The short answer is no — not automatically, and probably not as soon as you'd hope. Two gates stand between your current product and a U.S. shelf, and neither is about the molecule.

Gate 1: the exclusivity timeline

The FDA finalized bemotrizinol on June 9, 2026, effective August 9, 2026. But the approval carries roughly 18 months of exclusivity tied to the original data submission. During that window, other companies can't rely on that data to market their own bemotrizinol sunscreens — which pushes broad third-party U.S. entry to around late 2027, unless you license the ingredient or generate your own qualifying data.

In other words: the door is opening, but it isn't open yet. The brands that win the post-exclusivity rush are the ones who spend this window getting compliant — not the ones who start the paperwork after a competitor lands first.

Gate 2: in the U.S., sunscreen is a drug

This is the part most international brands underestimate. In Korea, Japan, and the EU, sunscreens are cosmetics. In the United States, sunscreens are OTC drugs — and a permitted active ingredient doesn't change that. Your formula may be fine, but the product still has to clear OTC drug requirements:

• Establishment registration for every facility that makes or processes it.

• Drug listing — an NDC and an electronic SPL submission for each product.

• A U.S. Drug Facts panel — not your home-market label.

• SPF and broad-spectrum testing on the final formulation, to U.S. methods.

• A U.S. Agent, because you're a foreign establishment.

• Serious adverse event reporting to the FDA.

  
  

What usually has to change on your label

Even a great formula rarely ships with a U.S.-ready label. Expect to rework the Drug Facts format, the active-ingredient declaration, the required warnings and directions, and any SPF, broad-spectrum, or water-resistance claims so they match your U.S. test results. Assume your current label needs changes rather than hoping it passes as-is.

What to do while you wait for the window

1. Confirm your pathway — monograph (exclusivity clock), license, or your own data.

2. Audit your existing label against the U.S. Drug Facts format.

3. Line up final-formulation SPF and broad-spectrum testing.

4. Appoint a U.S. Agent and map your registration and listing obligations.

5. Build the file now so you're submission-ready the day your window opens.

   
   

Get the checklist

We've put every step into a practical Bemotrizinol (BEMT) U.S. Market-Entry Compliance Checklist, with the timeline built in. Download the free checklist → Prefer to hand it off? Axentra's U.S. Market Entry Package covers assessment, labeling, registration, listing, U.S. Agent, and ongoing compliance end to end.

---

Frequently asked questions

Can I sell my Korean or Japanese sunscreen in the U.S. right now?

Not simply because bemotrizinol is approved. The order is effective August 9, 2026, but the ~18-month exclusivity means most brands relying on the monograph realistically reach the market around late 2027 — and the product still has to meet all U.S. OTC drug requirements first.

Is my product automatically compliant because the ingredient is approved?

No. A permitted active is one piece. You still need a compliant Drug Facts label, U.S. testing, establishment registration, drug listing, and a U.S. Agent.

Do I need a U.S. Agent?

Yes. Any foreign establishment that registers with the FDA must designate a U.S. Agent as its point of contact with the agency.